



Aetna Better Health[®] of Kentucky

NEW POLICY UPDATES

CLINICAL PAYMENT, CODING AND POLICY CHANGES

We regularly augment our clinical, payment and coding policy positions as part of our ongoing policy review processes. In an effort to keep our providers informed, please see the below chart of upcoming new policies.

Effective for dates of service beginning July 1, 2025

Drugs and Biologicals Policies:

Aetna Better Health of Kentucky supports FDA label, off-label compendia (Micromedex, Clinical Pharmacology, National Comprehensive Cancer Network, Lexi-Drugs, American Hospital Formulary Service Drug Information[®]), AMA/CPT, state Medicaid guidelines and other sources for Drugs and Biologicals. These supported policies include:

- Indication (FDA-label and off-label approved compendia indications)
- Dosage (based on indication and supported by FDA-label and off-label approved compendia)
- Frequency (based on indication and supported by FDA-label and off-label approved compendia)
- Route of administration (based on category of drug, FDA-label, off-label approved compendia, and AMA/CPT guidelines)
- Age restrictions
- Combination therapy with other required drugs/substances (based on FDA-label and approved off-label compendia guidelines by indication)

New Drug/Biological Policies

Infliximab (J1745, Q5103, Q5104, Q5109, Q5121)

New policies for Infliximab:

Dosage-

- Daily limits added for patients aged 15 and 18 years of age and the diagnosis on the claim is plaque psoriasis (pediatric), pustular psoriasis, or regional enteritis (pediatric).
- Limits over time added for patients aged 15 and 18 years of age and the diagnosis on the claim is plaque psoriasis (pediatric) or regional enteritis (pediatric).

-Limits over time added for patients 18 years of age or older and the diagnosis on the claim is ulcerative colitis (adult).

Visits-

-Added limit of number of visits over time allowed for patients 18 years of age or older and the diagnosis on the claim is ulcerative colitis (adult)..